Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial.

Abstract in brief

• The study compared the effectiveness and safety of 2 mg versus 4 mg tolterodine ER, both combined with a blocker, in men with persistent urinary symptoms despite previous blocker treatment.
• Both dosage groups showed significant improvements in urinary symptoms, with no significant differences between the 2 mg and 4 mg doses in symptom relief, bladder diary measures, or patient-reported outcomes, and both were well tolerated.
• The findings suggest that a lower dose of tolterodine ER (2 mg) is as effective and safe as the standard dose (4 mg) when added to bladder blockers for treating residual storage symptoms in men.]